Lineage Cell Therapeutics (LCTX) Current Deferred Revenue (2010 - 2026)

Lineage Cell Therapeutics has reported Current Deferred Revenue for 17 years, with the latest figure at $1.7 million in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue fell 75.24% year-over-year to $1.7 million; the trailing twelve-month figure through Mar 2026 stood at $1.7 million (down 75.24% YoY), and the FY2025 full-year result was $3.3 million, down 54.89% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $1.7 million, down from $3.3 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $41.5 million in Q2 2022, with the low at $1.7 million in Q1 2026.
• Historically, Current Deferred Revenue has averaged $13.2 million across 5 years, with a median of $9.4 million in 2022.
• Annual changes were most pronounced in 2022 — Current Deferred Revenue soared 14637.62% — and 2026, when it slumped 75.24%.
• Lineage Cell Therapeutics' Current Deferred Revenue stood at $9.4 million in 2022, then advanced by 14.72% to $10.8 million in 2023, then sank by 31.64% to $7.4 million in 2024, then sank by 54.89% to $3.3 million in 2025, then slumped by 48.51% to $1.7 million in 2026.
• The last three Current Deferred Revenue figures came in at $1.7 million (Q1 2026), $3.3 million (Q4 2025), and $3.8 million (Q3 2025), per Business Quant data.